Anti-blindness drug Avastin 'could save NHS £84m a year'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.An anti-blindness injection that a rival drugs manufacturer wants to prevent the NHS from using could save the health service £84m a year.
Avastin, which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly – costs only £60 per injection.
But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot.
Avastin is intended to treat cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.
The study, presented at a conference by the Association for Research and Ophthalmology, looks set to further enflame a dispute between the NHS and the maker of Lucentis, Novartis.
Some doctors have been prescribing Avastin for the condition to save money, even though it has not licensed for this use. However, that has led Novartis to take four NHS trusts to court to prevent their doctors from doing so, arguing its unsanctioned use undermines patient safety.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments